This is a working overview of SR9009, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-20 and is reviewed periodically as new material appears.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
=== Osteoporosis === Vitamin K is required for the gamma-carboxylation of osteocalcin in bone. The risk of osteoporosis, assessed via bone mineral density and fractures, was not affected for people on warfarin therapy – a vitamin K antagonist. Studies investigating whether vitamin K supplementation reduces risk of bone fractures have shown mixed results.
== Further reading == Bshara, Khaldun (2025). "Settler Colonialism Rebranded: Trump's Gaza Plan and the Capitalist Logic of War". Journal of Palestine Studies. 54: 62–70. doi:10.1080/0377919X.2025.2489264.
== Personal life == Alwyn and Aaron Davey are cousins of Brownlow medallist Gavin Wanganeen. Alwyn was named after his father. Davey's twin sons, Alwyn Jr and Jayden were drafted to Essendon in the 2022 AFL draft, under the father–son rule.
== Chemistry == Crisaborole (chemical name: 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile) is a member of the class of benzoxaboroles characterized by the presence of a boronic acid hemiester with a phenolic ether and a nitrile. Crisaborole crystallizes into two polymorphs that differ in the conformation of the oxaborole ring. A cocrystal with 4,4'-bipyridine has been prepared and studied by X-ray crystallography.
Sources: en.wikipedia.org
=== Austro-Prussian War and Province of Prussia === In 1866, the Austro-Prussian War broke out, in which Prussia quickly defeated Austria and its allies. In the 1866 Peace of Prague, Prussia gained Holstein in addition to Schleswig and Lauenburg. Contrary to the hopes of German Schleswig-Holsteiners, the area did not gain its independence, but was annexed to Prussia, becoming the Province of Schleswig-Holstein in 1868; Lauenburg remained a separate entity until it was incorporated as Kreis Herzogtum Lauenburg in 1876. The Peace of Prague also led to the dissolution of the loose (confederal) Austrian-led German Confederation and the establishment of the far more integrated (federal) Prussian-led North German Confederation, of which Schleswig-Holstein was now part as a Prussian Province; the North German Confederation became the German Empire in 1871. Section five of the Peace of Prague had also stipulated that the people of Northern Schleswig would be consulted in a referendum on whether to remain under Prussian rule or return to Danish rule. This condition, however, was never fulfilled by Prussia. During the decades of Prussian rule within the German Empire, authorities attempted a Germanisation policy in the northern part of Schleswig, which remained predominantly Danish. The period also meant increased industrialisation of Schleswig-Holstein and the use of Kiel and Flensburg as important Imperial German Navy locations. The northernmost part and the west coast of the province saw a wave of emigration to America, while some Danes of North Schleswig emigrated to Denmark.
==== March 2008 hepatitis ==== In March and April 2008, the Community Epidemiology Branch of the San Diego County Health and Human Services Agency traced a hepatitis A outbreak in San Diego County to a single Chipotle restaurant located in La Mesa, California, in which 22 customers were infected with the virus.
Many factors must be considered with intracerebroventricular injection to maintain safety. Some of these factors include osmolarity, pH, volume, and the presence of preservatives in the drug solution. Also, intracranial pressure, cerebrospinal fluid bulk flow rate, and buffering capacity have an impact on the distribution and safety of the injected drug. A major concern of ICV injection is neurovascular injury and intracranial hemorrhage. The risk of these conditions increases with each additional injection or "tap". For this reason, if repeated taps are needed, a catheter-based device can be implanted. These devices are connected to a subcutaneous reservoir, the most common being the Ommaya reservoir. This can be accessed multiple times, with a sterile puncture through the scalp into the reservoir. There is also an associated risk of infection with this method, but it is less likely than other methods of accessing the intraventricular space. Other rare complications with this method include leukoencephalopathy, white matter necrosis, and intracerebral hemorrhage. Other complications can occur with this procedure, and they can be divided into infectious and noninfectious categories. Of the noninfectious complications, the most frequently reported were CSF leaks, hemorrhage, catheter malposition, catheter obstruction, and device malfunction. In one study, the most likely cause for device removals was due to infectious complications (73.75 percent). Of the infections, the most common cause was skin flora.
== Genome == An. gambiae s.s. genomes have been sequenced three times, once for the M strain, once for the S strain, and once for a hybrid strain. Currently, ~90 miRNA have been predicted in the literature (38 miRNA officially listed in miRBase) for An. gambiae s.s. based upon conserved sequences to miRNA found in Drosophila. Holt et al., 2002 and Neafsey et al., 2016 find transposable elements to be ~13% of the genome, similar to Drosophila melanogaster (also in Diptera). However they find the proportion of TE types to be very different from D. melanogaster with approximately the same composition of long terminal repeat retrotransposons, non-long terminal repeat retrotransposons and DNA transposons. These proportions are believed to be representative of the genus. The genetics and genomics of sex chromosomes have been discovered and studied by Windbichler et al., 2007 and Galizi et al., 2014 (a Physarum polycephalum homing endonuclease which destroys X chromosomes), Windbichler et al., 2008 and Hammond et al., 2016 (methods to reduce the female population), Windbichler et al., 2011 (trans from yeast), Bernardini et al., 2014 (a method to increase the male population), Kyrou et al., 2018 (a female necessary exon and a homing endonuclease to drive it), Taxiarchi et al., 2019 (sex chromosome dynamics in general) and Simoni et al., 2020 (an X chromosome destroying site specific nuclease). See § Gene drive below for their applications. An. gambiae has a high degree of polymorphism.
A mimotope is often a peptide, and mimics the structure of an epitope. Because of this property it causes an antibody response similar to the one elicited by the epitope. An antibody for a given epitope antigen will recognize a mimotope which mimics that epitope. Mimotopes are commonly obtained from phage display libraries through biopanning. Vaccines utilizing mimotopes are being developed. Mimotopes are a kind of peptide aptamers. When the term mimotope was coined by Mario Geysen in 1986, it was used to describe peptides mimicking epitopes. However, this concept has been extended to refer peptide mimic of all types of binding sites. As the mimic of binding site, mimotope analysis has been widely used in mapping epitopes, identifying drug target and inferring protein interaction networks. Furthermore, mimotope has also shown its potential in the development of new diagnostics, therapeutics and vaccines. In addition, special affinities mediated by mimotopes to various semiconductors and other materials have shown very encouraging promise in new material and new energy studies. Gathering information on mimotopes into a special database therefore deserves. In 2010, the MimoDB database version 1.0 was released. It had 10716 peptides grouped into 1229 sets. These peptides were extracted from biopanning results of phage-displayed random peptide libraries reported in 571 papers. The MimoDB database has been updated to the current version 2.0 very recently. In version 2.0, it has 15633 peptides collected from 849 papers and grouped into 1818 sets.
Sources: en.wikipedia.org
Roseanne says Darlene must first finish high school, but after learning David threatened to break up with her if she goes, she demands Darlene attend, giving Darlene an opportunity to become the writer Roseanne wanted to be. Darlene, who had decided not to attend, reveals her real reason for declining admission is because she fears failing, but finally agrees to go. At college, Darlene begins dating Jimmy while still seeing David, who initially accepts this arrangement in order to be with Darlene. When he later demands she choose between them, Darlene chooses Jimmy, though he later breaks off their relationship due to Darlene's inability to be close. Darlene realizes she still loves David and they reconcile. Darlene and David marry after Darlene becomes pregnant, giving birth to a daughter, Harris Conner-Healy. Harris is born three months premature and David and Darlene must decide whether or not to keep her on life support or allow nature to determine her fate. Harris proves strong enough to survive on her own. In the final episode of Season 9, it is revealed that Darlene was actually dating Mark, and Becky was with David, though Roseanne had written in her book that Darlene being with David made more sense. However, by the start of Season 10, which takes place twenty years later, this revelation has been retconned out of existence. In Season 10, Darlene is now a single mother of two children, teen daughter Harris and ten-year-old son Mark.
== External links == Clinical trial number NCT02666664 for "Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)" at ClinicalTrials.gov Clinical trial number NCT02988115 for "Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant (CLEAR Serenity)" at ClinicalTrials.gov Clinical trial number NCT02991118 for "Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk (CLEAR Wisdom)" at ClinicalTrials.gov
Calcitonin gene-related peptide 2 (CGRP2), also called calcitonin related polypeptide beta, is a hormone that in humans is encoded by the CALCB gene (previously CALC2). Like the related hormone, calcitonin gene-related peptide 1 (CGRP1), this hormone induces vasodilation (relaxation of blood vessels) through the activation of the CGRP receptor. This form of calcitonin gene-related peptide is traditionally considered to be the primary form used in the enteric nervous system (nervous system in the gut). The gene that encodes CGRP1, CALCA, also encodes the blood-calcium-reducing hormone calcitonin, but despite its name, this protein is encoded by a distinct gene (CALCB). This hormone activates the CGRP receptor, which is a two protein (heterodimer) complex that is composed of RAMP1 and CALCRL.
=== Thorium-230 === 230Th is a radioactive isotope of thorium that can be used to date corals (uranium-thorium dating) and determine ocean current flux. Ionium (symbol Io) was the name given early in the study of radioactive elements to the 230Th isotope produced in the decay chain of 238U before the nature of isotopes was fully realized. The name is still used in ionium–thorium dating, another dating method using this isotope.
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.